UBAM Swiss Equity I+C CHFRegister to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | - | - | - | 10.5 | 6.8 | |
+/-Cat | - | - | - | -0.4 | 3.1 | |
+/-B’mrk | - | - | - | 1.9 | 2.7 | |
Category: Switzerland Equity | ||||||
Category Benchmark: Morningstar Switzerland TME... |
Key Stats | ||
NAV 20/11/2024 | CHF 94.39 | |
Day Change | -0.29% | |
Morningstar Category™ | Switzerland Equity | |
ISIN | LU2440849235 | |
Fund Size (Mil) 20/11/2024 | CHF 1726.30 | |
Share Class Size (Mil) 20/11/2024 | CHF 474.64 | |
Max Initial Charge | - | |
Ongoing Charge 01/11/2024 | 0.46% |
Investment Objective: UBAM Swiss Equity I+C CHF |
This sub-fund invests its net assets primarily in equities and other similar transferable securities, in addition to, on an ancillary basis, warrants on transferable securities, convertible bonds or bonds with warrants on transferable securities, bonds and other debt securities, money market instruments, issued primarily by companies (i) having their registered office, or (ii) carrying on a major part of their commercial activity, or (iii) as holding companies owning predominant interests in companies with their registered office in Switzerland. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Eléanor Taylor Jolidon 01/01/2008 | ||
Martin Moeller 30/06/2006 | ||
Inception Date 07/02/2022 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
SIX SPI TR CHF | Morningstar Switzerland TME NR CHF |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for UBAM Swiss Equity I+C CHF | 31/10/2024 |
|
|
Top 5 Holdings | Sector | % |
Novartis AG Registered Shares | Healthcare | 7.33 |
ABB Ltd | Industrials | 6.94 |
Roche Holding AG | Healthcare | 6.61 |
Nestle SA | Consumer Defensive | 6.26 |
UBS Group AG | Financial Services | 6.08 |
Increase Decrease New since last portfolio | ||
UBAM Swiss Equity I+C CHF |